See more : L&C Bio Co., Ltd (290650.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of ORIC Pharmaceuticals, Inc. (ORIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ORIC Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bioptik Technology Incorporation (4161.TWO) Income Statement Analysis – Financial Results
- WithSecure Oyj (WITH.HE) Income Statement Analysis – Financial Results
- Aprea Therapeutics, Inc. (APRE) Income Statement Analysis – Financial Results
- Giyani Metals Corp. (EMM.V) Income Statement Analysis – Financial Results
- Premium Nickel Resources Ltd. (PNRL.V) Income Statement Analysis – Financial Results
ORIC Pharmaceuticals, Inc. (ORIC)
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| Gross Profit | -1.03M | -966.00K | -897.00K | -970.00K | -1.00M | -900.00K | -900.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 85.17M | 61.68M | 56.86M | 35.92M | 22.84M | 19.03M | 19.13M |
| General & Administrative | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 3.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -900.00K |
| SG&A | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 2.52M |
| Other Expenses | 0.00 | 5.00M | 15.00K | 177.00K | 289.00K | 233.00K | 0.00 |
| Operating Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 21.64M |
| Cost & Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 22.54M |
| Interest Income | 10.08M | 2.65M | 141.00K | 306.00K | 1.40M | 775.00K | 251.00K |
| Interest Expense | 0.00 | 2.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| EBITDA | -109.75M | -91.77M | -77.97M | -74.19M | -27.54M | -20.46M | -21.13M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -110.78M | -91.77M | -78.87M | -74.19M | -28.57M | -22.37M | -22.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.08M | 2.65M | 156.00K | 483.00K | 1.69M | 1.01M | 512.00K |
| Income Before Tax | -100.70M | -89.12M | -78.72M | -73.70M | -26.88M | -21.36M | -22.03M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.36M | -1.04M | 23.57M | -1.40M | -1.01M | 0.00 |
| Net Income | -100.70M | -91.48M | -77.68M | -97.27M | -25.49M | -21.36M | -22.03M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EPS Diluted | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| Weighted Avg Shares Out | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
| Weighted Avg Shares Out (Dil) | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
Source: https://incomestatements.info
Category: Stock Reports